RWC Asset Management LLP Has $287,000 Stake in Boston Scientific Co. (NYSE:BSX)

RWC Asset Management LLP grew its stake in shares of Boston Scientific Co. (NYSE:BSX) by 18.3% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 3,216 shares of the medical equipment provider’s stock after buying an additional 498 shares during the period. RWC Asset Management LLP’s holdings in Boston Scientific were worth $287,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Private Advisor Group LLC raised its holdings in Boston Scientific by 2.7% in the 3rd quarter. Private Advisor Group LLC now owns 36,003 shares of the medical equipment provider’s stock valued at $3,017,000 after acquiring an additional 944 shares in the last quarter. PFG Investments LLC increased its position in shares of Boston Scientific by 3.3% during the third quarter. PFG Investments LLC now owns 7,988 shares of the medical equipment provider’s stock valued at $669,000 after purchasing an additional 258 shares during the period. Wealth Enhancement Advisory Services LLC raised its stake in shares of Boston Scientific by 123.1% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 158,538 shares of the medical equipment provider’s stock valued at $13,285,000 after purchasing an additional 87,470 shares in the last quarter. State of Alaska Department of Revenue lifted its position in Boston Scientific by 1.7% in the third quarter. State of Alaska Department of Revenue now owns 178,166 shares of the medical equipment provider’s stock worth $14,929,000 after purchasing an additional 2,955 shares during the period. Finally, Cavalier Investments LLC boosted its stake in Boston Scientific by 6.7% during the third quarter. Cavalier Investments LLC now owns 71,841 shares of the medical equipment provider’s stock worth $6,020,000 after buying an additional 4,485 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Boston Scientific Price Performance

BSX opened at $104.44 on Monday. The stock has a market cap of $154.12 billion, a P/E ratio of 83.55, a P/E/G ratio of 2.79 and a beta of 0.80. Boston Scientific Co. has a 12 month low of $65.52 and a 12 month high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The company has a fifty day simple moving average of $97.98 and a 200 day simple moving average of $89.49.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, research analysts expect that Boston Scientific Co. will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on BSX. Wells Fargo & Company increased their price objective on shares of Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a research note on Thursday, February 6th. UBS Group raised their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. Needham & Company LLC reiterated a “hold” rating on shares of Boston Scientific in a research note on Thursday, February 6th. Citigroup boosted their target price on shares of Boston Scientific from $107.00 to $122.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. Finally, Raymond James raised their price target on Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a report on Thursday, February 6th. Two equities research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $107.39.

Insiders Place Their Bets

In other news, EVP Wendy Carruthers sold 6,983 shares of the stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the sale, the executive vice president now owns 29,308 shares of the company’s stock, valued at $2,660,580.24. This represents a 19.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP John Bradley Sorenson sold 4,119 shares of the firm’s stock in a transaction on Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total transaction of $370,792.38. Following the sale, the executive vice president now owns 35,319 shares in the company, valued at approximately $3,179,416.38. The trade was a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 139,630 shares of company stock worth $14,467,616. Company insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.